Cost effectiveness analysis of recombinant human Pro urokinase and alteplase in treatment of acute ST-segment elevation myocardial infarction
GAO Sheng-nan
LIU Guo-qiang
Abstract：Objective:To compare the cost-effectiveness between alteplase and recombinant human Pro urokinase in treatment of acute ST-segment elevation myocardial infarction.Methods:A total of 133 STEMI patients admitted during 2016 were divided into alteplase group and recombinant human Pro urokinase group.In the two groups,clinical myocardial infarction thrombolytic recanalization rate,adverse reaction rate were evaluated,and the C/E was analyzed.Results:There was no significant difference in clinical myocardial infarction thrombolytic recanalization rate between alteplase group and recombinant human Pro urokinase group.In recombinant human Pro urokinase group,the incidence rate of adverse reactions was significantly lower than this in the alteplase group (P ＜0.01).The C/E ratio in recombinant human Pro urokinase group was 252.22 yuan,it was lower than that in alteplase group which was 253.62 yuan.ICER is 145.48.The results of sensitivity analysis and cost-effectiveness analysis are consistent.Conclusion:Recombinant human Pro urokinase in treatment of STEMI has good curative effect,less adverse reactions and the advantages of cost effectiveness.Recombinant human Pro urokinase is the optimum scheme.
Keywords：acute ST-segment elevation myocardial infarctionrecombinant human Pro urokinasealteplasecost effectiveness analysis
Publication Date：2017-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：4( 1725-1728 )